Literature DB >> 11574456

Effect of repaglinide addition to NPH insulin monotherapy on glycemic control in patients with type 2 diabetes.

D A de Luis, R Aller, L Cuellar, C Terroba, H Ovalle, O Izaola, E Romero.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11574456     DOI： 10.2337/diacare.24.10.1844

Source DB:  PubMed          Journal:  Diabetes Care        ISSN： 0149-5992            Impact factor:   19.112


× No keyword cloud information.
  7 in total

Review 1.  Japanese Clinical Practice Guideline for Diabetes 2016.

Authors:  Masakazu Haneda; Mitsuhiko Noda; Hideki Origasa; Hiroshi Noto; Daisuke Yabe; Yukihiro Fujita; Atsushi Goto; Tatsuya Kondo; Eiichi Araki
Journal:  Diabetol Int       Date:  2018-03-27

Review 2.  Japanese Clinical Practice Guideline for Diabetes 2019.

Authors:  Eiichi Araki; Atsushi Goto; Tatsuya Kondo; Mitsuhiko Noda; Hiroshi Noto; Hideki Origasa; Haruhiko Osawa; Akihiko Taguchi; Yukio Tanizawa; Kazuyuki Tobe; Narihito Yoshioka
Journal:  Diabetol Int       Date:  2020-07-24

Review 3.  Insulin monotherapy compared with the addition of oral glucose-lowering agents to insulin for people with type 2 diabetes already on insulin therapy and inadequate glycaemic control.

Authors:  Rimke C Vos; Mariëlle Jp van Avendonk; Hanneke Jansen; Alexander N Goudswaard; Maureen van den Donk; Kees Gorter; Anneloes Kerssen; Guy Ehm Rutten
Journal:  Cochrane Database Syst Rev       Date:  2016-09-18

Review 4.  The role of sulphonylureas in the management of type 2 diabetes mellitus.

Authors:  Marc Rendell
Journal:  Drugs       Date:  2004       Impact factor: 9.546

5.  Japanese Clinical Practice Guideline for Diabetes 2019.

Authors:  Eiichi Araki; Atsushi Goto; Tatsuya Kondo; Mitsuhiko Noda; Hiroshi Noto; Hideki Origasa; Haruhiko Osawa; Akihiko Taguchi; Yukio Tanizawa; Kazuyuki Tobe; Narihito Yoshioka
Journal:  J Diabetes Investig       Date:  2020-07       Impact factor: 4.232

6.  The investigation of the efficacy of insulin glargine on glycemic control when combined with either repaglinide or acarbose in obese Type 2 diabetic patients.

Authors:  C Duran; E Tuncel; C Ersoy; I Ercan; H Selimoglu; S Kiyici; M Guclu; E Erturk; S Imamoglu
Journal:  J Endocrinol Invest       Date:  2009-01       Impact factor: 4.256

7.  Japanese Clinical Practice Guideline for Diabetes 2016.

Authors:  Masakazu Haneda; Mitsuhiko Noda; Hideki Origasa; Hiroshi Noto; Daisuke Yabe; Yukihiro Fujita; Atsushi Goto; Tatsuya Kondo; Eiichi Araki
Journal:  J Diabetes Investig       Date:  2018-03-26       Impact factor: 4.232
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.